ORPOF (OSE Immunotherapeutics) Stock Based Compensation: $1.72 Mil (TTM As of Dec. 2025)


ORPOF OSE Immunotherapeutics SA ORPOF
41 GF Score
Price $4.43
GF Value $1.76
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Stock Based Compensation?

OSE Immunotherapeutics ORPOF 41 Stock Based Compensation is $1.72 Mil as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 41/100 and a GF Value™ of $1.76 (Significantly Overvalued). The stock has 6 warning signs investors should review.

OSE Immunotherapeutics's Stock Based Compensation for the six months ended in Dec. 2025 was $-0.37 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $1.72 Mil.

OSE Immunotherapeutics Stock Based Compensation Related Terms

OSE Immunotherapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics Stock Based Compensation Chart

OSE Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.33 2.89 1.90 2.19 1.75

OSE Immunotherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.95 1.27 2.10 -0.37
ORPOF
41GF Score
OSE Immunotherapeutics SA ORPOF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OSE Immunotherapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.72 Mil.

What does a Stock Based Compensation of $1.72 Mil mean?
OSE Immunotherapeutics (ORPOF) has a Stock Based Compensation of $1.72 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for OSE Immunotherapeutics and its competitors.
Is OSE Immunotherapeutics' Stock Based Compensation too high?
OSE Immunotherapeutics' current Stock Based Compensation is $1.72 Mil. Overall, OSE Immunotherapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' Stock Based Compensation compare to VRTX and REGN?
OSE Immunotherapeutics' Stock Based Compensation of $1.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current Stock Based Compensation is $1.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.76, compared to a current price of $4.43 — trading 151.7% above its estimated fair value. The current Stock Based Compensation is $1.72 Mil. OSE Immunotherapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current Stock Based Compensation is $1.72 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of $4.43 is trading 151.7% above its estimated GF Value™ of $1.76. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for ORPOF:

  • Stock Based Compensation: $1.72 Mil
  • GF Value™: $1.76 vs. price of $4.43 (151.7% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
41GF Score

Get the complete analysis for ORPOF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.43
Price
$1.76
GF Value